Shuttle Pharmaceuticals Holdings, Inc.
SHPHNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$3.76
+$0.05 · +1.35%
SHPH company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
17
Strong Down
Sentiment
53
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteShuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Christopher Robert Cooper
- Listed since
- Aug 31, 2022
- Employees
- 2
Market position
Day range
Current $3.76
52-week range
Current $3.76
- Open
- $3.74
- Previous close
- $3.71
- Volume
- 10.43K
- 0.01× average
- Average volume
- 2.07M
- Average daily volume
- Market cap
- 2.2M USD
- Beta
- 1.22
- Market reference 1
- 50-day average
- $3.6333
- +3.49% above average
- 200-day average
- $10.5965
- -64.52% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.85M USD
- P/E (TTM)
- -0.06×
- P/B (TTM)
- 0.57×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.25×
- Earnings yield
- -397.58%
- Free cash flow yield
- -321.60%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -519.94%
- Return on assets
- -111.89%
- Return on invested capital
- -460.77%
Financial health
- Debt / equity
- 0.06×
- Current ratio
- 0.06×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 5.97K USD | 60.83K USD |
| Gross profit | — | — | — | −5.97K USD | −60.83K USD |
| Research and development | 4.05M USD | 3.62M USD | 3.52M USD | 1.05M USD | 1.02M USD |
| Selling, general, and administrative | 7.86M USD | 4.08M USD | 2.38M USD | 1.29M USD | 721.18K USD |
| Operating expenses | 11.92M USD | 7.7M USD | 5.89M USD | 2.34M USD | 1.68M USD |
| Interest income | 1.09K USD | 38.14K USD | 79.12K USD | — | — |
| Interest expense | 70.83K USD | 1.36M USD | 2.6M USD | 670.61K USD | 50.79K USD |
| Depreciation and amortization | 290.11K USD | 5.46K USD | 6.81K USD | 5.97K USD | 60.83K USD |
| Operating income | −11.92M USD | −7.7M USD | −5.89M USD | −2.34M USD | −1.74M USD |
| Net income | −11.72M USD | −9.14M USD | −6.59M USD | −5M USD | −1.15M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -4.3
EPS: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 11, 2026 | 1:10 | — | — |
Stock split | Jun 16, 2025 | 1:25 | — | — |
Stock split | Aug 13, 2024 | 1:8 | — | — |
Effective Jun 11, 2026
1:10
Effective Jun 16, 2025
1:25
Effective Aug 13, 2024
1:8
SHPH peers
Continue in GoAI
Research SHPHresearch.disclaimer